1. Stein H, Warnke RA, Chan WC, Jaffe ES, Chan JKC, Gatter KC, Campo E (2008) Diffuse large B-cell lymphoma,not otherwise specified. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tisseus, 4th edn. International Agency for Research on Cancer (IARC), Lyon, pp 233–237
2. Wu G, Keating A (2006) Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer 106:247–257. doi: 10.1002/cncr.21586
3. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851–1861. doi: 10.1182/blood-2004-07-2947
4. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947. doi: 10.1056/NEJMoa012914
5. Sebestyen A, Sticz TB, Mark A, Hajdu M, Timar B, Nemes K, Nagy N, Varadi Z, Kopper L (2012) Activity and complexes of mTOR in diffuse large B-cell lymphomas—a tissue microarray study. Mod Pathol Off J U S Canad Acad Pathol Inc 25:1623–1628. doi: 10.1038/modpathol.2012.141